Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Mult Scler. 2010 Jun;16(6):707-14. doi: 10.1177/1352458510367462.

Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis.

Author information

  • 1Oxford Centre for Enablement, Windmill Road, Oxford, OX3 7LD, UK. derick.wade@noc.nhs.uk

Abstract

OBJECTIVE:

To determine the efficacy of Sativex (USAN: nabiximols) in the alleviation of spasticity in people with multiple sclerosis.

METHODS:

The results from three randomized, placebo-controlled, double-blind parallel group studies were combined for analysis.

PATIENTS:

666 patients with multiple sclerosis and spasticity.

MEASURES:

A 0-100 mm Visual Analogue Scale (VAS, transformed to a 0-10 scale) or a 0-10 Numerical Rating Scale (0-10 NRS) was used to measure spasticity. Patients achieving a > or =30% improvement from baseline in their spasticity score were defined as 'responders'. Global impression of change (GIC) at the end of treatment was also recorded.

RESULTS:

The patient populations were similar. The adjusted mean change of the numerical rating scale from baseline in the treated group was -1.30 compared with -0.97 for placebo. Using a linear model, the treatment difference was -0.32 (95% CI -0.61, -0.04, p = 0.026). A statistically significant greater proportion of treated patients were responders (odds ratio (OR) = 1.62, 95% CI 1.15, 2.28; p = 0.0073) and treated patients also reported greater improvement: odds ratio 1.67 (95% CI 1.05, 2.65; p = 0.030). High numbers of subjects experienced at least one adverse event, but most were mild to moderate in severity and all drug-related serious adverse events resolved.

CONCLUSION:

The meta-analysis demonstrates that nabiximols is well tolerated and reduces spasticity.

PMID:
20558502
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire
    Loading ...
    Write to the Help Desk